[go: up one dir, main page]

WO2004091507A3 - Optimal polyvalent vaccine for cancer - Google Patents

Optimal polyvalent vaccine for cancer Download PDF

Info

Publication number
WO2004091507A3
WO2004091507A3 PCT/US2004/011122 US2004011122W WO2004091507A3 WO 2004091507 A3 WO2004091507 A3 WO 2004091507A3 US 2004011122 W US2004011122 W US 2004011122W WO 2004091507 A3 WO2004091507 A3 WO 2004091507A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
polyvalent vaccine
cell line
provides
optimal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/011122
Other languages
French (fr)
Other versions
WO2004091507A2 (en
Inventor
Philip O Livingston
Govindaswami Ragupathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to CA002521812A priority Critical patent/CA2521812A1/en
Priority to JP2006509902A priority patent/JP2006522828A/en
Priority to EP04759415A priority patent/EP1615614A4/en
Publication of WO2004091507A2 publication Critical patent/WO2004091507A2/en
Priority to US11/246,752 priority patent/US20060035267A1/en
Anticipated expiration legal-status Critical
Publication of WO2004091507A3 publication Critical patent/WO2004091507A3/en
Priority to US12/089,302 priority patent/US20080241195A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of: a) selection of an appropriate cancer cell line; and b) detection of the expression of antigens on the surface of said cell line of the cancer, wherein the antigens expressed will be used in the polyvalent vaccine. This invention also provides a method for identification of the optimal combination of a polyvalent vaccine against a cancer comprising steps of: a) selection of an appropriate cancer cell line and b) detection of the immunogenicity will be used in the polyvalent vaccine. This invention provides various uses of the identified polyvalent vaccine.
PCT/US2004/011122 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer Ceased WO2004091507A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002521812A CA2521812A1 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer
JP2006509902A JP2006522828A (en) 2003-04-09 2004-04-09 Optimal multivalent vaccine for cancer
EP04759415A EP1615614A4 (en) 2003-04-09 2004-04-09 OPTIMAL VERSATILE VACCINE AGAINST CANCER
US11/246,752 US20060035267A1 (en) 2003-04-09 2005-10-07 Optimal polyvalent vaccine for cancer
US12/089,302 US20080241195A1 (en) 2003-04-09 2006-10-06 Optimal Polyvalent Vaccine for Cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46162203P 2003-04-09 2003-04-09
US60/461,622 2003-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/246,752 Continuation-In-Part US20060035267A1 (en) 2003-04-09 2005-10-07 Optimal polyvalent vaccine for cancer

Publications (2)

Publication Number Publication Date
WO2004091507A2 WO2004091507A2 (en) 2004-10-28
WO2004091507A3 true WO2004091507A3 (en) 2005-12-15

Family

ID=33299843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011122 Ceased WO2004091507A2 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer

Country Status (4)

Country Link
EP (1) EP1615614A4 (en)
JP (1) JP2006522828A (en)
CA (1) CA2521812A1 (en)
WO (1) WO2004091507A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (en) 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
US9125848B2 (en) 2010-06-10 2015-09-08 The Cleveland Clinic Foundation Alpha lactalbumin immunization methods
AU2013249522A1 (en) * 2012-04-16 2014-10-30 The Cleveland Clinic Foundation Multivalent breast cancer vaccine
JP2015227292A (en) * 2014-05-30 2015-12-17 国立大学法人高知大学 Pancreatic cancer cell invasion metastasis suppression vaccine
JP2019525138A (en) * 2016-06-16 2019-09-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Assay methods and methods for determining antibodies that induce CDC

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (en) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUSSELLI C ET AL: "Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience", J. CANCER RES. CLIN. ONCOL., vol. 127, no. 2, October 2001 (2001-10-01), pages R20 - 26, XP002259776 *
See also references of EP1615614A4 *

Also Published As

Publication number Publication date
EP1615614A4 (en) 2007-08-22
EP1615614A2 (en) 2006-01-18
CA2521812A1 (en) 2004-10-28
WO2004091507A2 (en) 2004-10-28
JP2006522828A (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AU2003236293A1 (en) Map matching method, map matching device, database for shape matching, and shape matching device
WO2004075850A3 (en) Polyvalent immunogen
WO2006023806A3 (en) A method and system for character recognition
WO2007044620A3 (en) Optimal polyvalent vaccine for cancer
AU2003224961A1 (en) System, method and portable device for biometric identification
WO2003039470A3 (en) Polyvalent immunogen of hiv
WO2005098609A8 (en) A method and system for character recognition
MXPA03007178A (en) Method, module, device and server for voice recognition.
WO2006017493A3 (en) Approach for creating a tag or attribute in a markup language document
WO2005111761A3 (en) System and method for creating tamper-resistant code
WO2009085025A3 (en) System and method for sparql-query processing using parametrized-sparql-query in dbms-based systems
WO2004110075A3 (en) Method for selecting an operating mode based on a detected synchronization pattern
EP1641586B8 (en) Method and device for pressure welding, which takes into account deviations in the length of workpieces
WO2001062283A3 (en) Mucosal adjuvant formulation
AU2003278196A1 (en) Method for the transmission, authentication and automatic processing of digitised documents
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2004091507A3 (en) Optimal polyvalent vaccine for cancer
AU2001271218A1 (en) Method and arrangement for identifying and processing commands in digital images, where the user marks the command, for example by encircling it
AU2003281558A1 (en) Probabilistic calculation element, drive method thereof, and recognition device using the same
WO2005016952A3 (en) Polyvalent immunogen
WO2005003897A3 (en) Method and apparatus for transferring a document into a folder
ITTO20010771A0 (en) AUTHENTICATION METHOD VIA STORAGE DEVICE.
FI20011063A0 (en) Method and apparatus for determining the position of the edge surface of pieces in a stack, e.g.
MXPA02011191A (en) Vaccines, immunotherapeutics and methods for using the same.
AU2002215993A1 (en) Method and device for determining the position, orientation and/or deformation of an object

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006509902

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2521812

Country of ref document: CA

Ref document number: 11246752

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004759415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004759415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11246752

Country of ref document: US